DeepLife
Created in 2019
Trend leader (A+)
Existing signals make this entity one of the most dynamic startupsSocial networks
44 3,399Activities
Technologies
Entity types
Location
75013 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 28
Engaged catalyst
21
0 0Added in Motherbase
4 years, 1 month ago
Value proposition
AI for digital twin of cells
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.
While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.
The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.
We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
Drug Discovery, Pharmaceutical, Deep Learning, and BiotechOriginal language
AI for digital twin of cells
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.
While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.
The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.
We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
DeepLife | Digital Twin of Cells for Drug Discovery
At DeepLife, we harness deep learning on multi-omics data to model cells and efficiently engineer their behavior
https://www.deeplife.co/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Digital Pharma Lab Health, Pharmaceutical, Business Consulting and Services | Digital Pharma Lab Health, Pharmaceutical, Business Consulting and Services | Not capitalistic Partnership Not event 22 Jun 2020 | | |